Analysts Ideas of the Week CardioComm Solutions - ECG Software Management

Transcription

1 Week of August 29, 2016 Analysts Ideas of the Week CardioComm Solutions - ECG Software Management Sid Rajeev, B.Tech, MBA, CFA Head of Research CardioComm Solutions - ECG Software Management This week, we are introducing CardioComm Solutions Inc. (TSXV: EKG). CardioComm, established in 1989, and based out of Toronto, is a global provider of consumer heart monitoring and medical electrocardiogram ( ECG ) device and management software solutions, with clients in over 20 countries. They have been a provider of choice for back-office ECG management software solutions for leading ECG device manufacturers. According to Kalorama Information, the global advanced patient monitoring market is worth approximately $31.4 billion. The company s technology is used in products for the recording, viewing, analyzing and storing of ECGs for diagnosis and management of cardiac patients. Their products / offerings include PC and LAN based products known as GEMS (Global ECG Management System), internet based SAAS and ASP software, and ECG reading services (see images below). The products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The company has received FDA, Health Canada, European Union CE Mark, Australian TGA and Chinese SFDA market clearances for its software and ECG devices.

2 Page 2 HEARTCHECK PEN ECG DEVICE HEARTCHECK ECG MONITOR (Rx) Source: Company The company has executed strategic partnership agreements to provide software solutions to major industry equipment and solution providers. The following are two examples of when CardioComm offering solutions to two majors: Philips Health Care (NYSE: PHG) - needed wireless mobile cardiac telemetry GE Medical (NYSE: GE) - needed an arrhythmia monitoring solution CardioComm has been extremely active in the recent past, with a number of developments. The following list highlights the key press releases in the past few months: July 5, 2016 CONTINUES TO EXPAND INTO M-HEALTH MARKETS WITH NEW ECG MONITORING LICENSE AND CO-MARKETING AGREEMENT June 28, 2016 UNVEILS THE HEARTCHECK EKG WRIST BAND FOR APPLE AND ANDROID SMARTPHONES

3 Page 3 June 20, 2016 SMART MONITORING ECG SOFTWARE TO INTERFACE WITH CARDIAC SENSING WEARABLE DEVICES FOR SMARTPHONE CONNECTED MEDICAL-WELLNESS MARKETS May 31, 2016 COMPLETES ARRHYTHMIA SURVEILLANCE DEAL FOR MONITORING HEART DISEASE PATIENTS TREATED WITH DRUG ELUTING STENTS IN INDIA April 26, 2016 April 18, 2016 EXECUTES HEARTCHECK HEALTH AND WELLNESS ECG SCREENING AGREEMENT IN THE REPUBLIC OF IRELAND INTRODUCES NEW HEARTCHECK ECG DEVICES AND ECG MONITORING SERVICES TO WELLNESS, HEALTH & SPORTS CLUB MARKETS The company also sees new opportunities in the ECG device space (wearable devices GSM enabled, blue tooth connected, etc.) as well as the ECG service space (see images below). Source: Company

4 Page 4 Brief biographies of the company s CEO and the Chairman are listed below: Etienne Grima - MSc, CHE, Chief Executive Officer Mr. Grima has over 22 years of experience in basic and clinical research administration, business development and strengthening corporate performance. Recognized for a unique and multidisciplinary approach to overseeing operational performance and fiscal resources, Mr. Grima joined the Board of Directors of CardioComm in December of In January of 2008 he was requested to serve as the company's Chief Financial Officer and Corporate Secretary during a period of organizational restructuring. In May of 2010 he accepted the position of Chief Executive Officer. Mr. Grima has also held the position of Chief Operating Officer and Financial Officer for the Canadian Heart Research Centre (CHRC) since its start in 1996 and a similar role in MD Primer Inc. since Prior to the CHRC, Etienne managed the St. Michael's Hospital (SMH) Health Sciences Research Centre in Toronto. Etienne guided SMH to become the fastest growing University of Toronto affiliated research center between 1994 and1997, acting as the signing officer on 350 externally funded clinical and basic research budgets, and overseeing the design, construction and maintenance of 27,000 square feet of clinical and basic research laboratories. During his tenure, Etienne developed a detailed understanding and methodology of the successful performance of clinical research within a hospital environment and became a member and Accredited Health Science Executive of the Canadian College of Health Service Executives. Etienne's educational background was rooted in his persistent interest in biology and he completed his academic career with an emphasis on human physiology, toxicology and zoology graduating from University of Toronto with high distinction in Etienne completed his graduate studies in 1986 with a Masters degree from the Faculty of Medicine, Department of Physiology, Centre for Research in Neurodegenerative and served as a peer reviewer for research publications and grant applications. Anatoly Langer - MD, M.Sc., FRCPC, FACC, Chairman of the Board Dr. Anatoly Langer graduated from the University of Manitoba in 1982 and completed his Internal Medicine and Cardiology training at the University of Toronto in He is a fellow of the American College of Cardiology and Canadian Royal College of Physicians and Surgeons. After two years as a Heart and Stroke Foundation Research Fellow he became a director of the Coronary Care Unit at St. Michael's Hospital in Toronto, Canada. In 1996 Dr. Langer founded Canadian Heart Research Centre with the goal of improving the care of cardiovascular patients through clinical trials research, physician and patient education and information sharing. Dr. Langer has over 250 peer reviewed publications, abstracts, and book chapters. His areas of interest and research include pathophysiology and management of acute and stable coronary syndromes as well as treatment and prevention of cardiovascular disease. More recently, Dr. Langer has been a keen participant in the development of electronic health record, web based applications for management of vital data and telemedicine. Since becoming a chair of the board of directors at a Canadian public company, CardioComm Solutions, Dr. Langer has championed the innovation for office and home based data acquisition and early disease management algorithms. Currently Dr. Langer is a Professor of Medicine at the University of Toronto and a staff cardiologist at St Michael's Hospital. He is a chair of the Canadian Heart Research Centre in Toronto.

5 Page 5 At the end of Q1-2016, CardioComm had approximately $40k in cash, and negative working capital of $0.7 million, with no debt. Q1 revenues were $0.37 million. The following table shows a summary of the company s recent financial performance. Key Financial Data (in C$); YE - Dec Q Q Revenues 1,504,994 1,725, , ,067 Net Income (954,899) (599,748) (389,878) (15,218) EPS (basic) (0.01) (0.01) (0.00) (0.00) Cash 174,744 98,184 69,802 40,271 Working Capital -662, , , ,476 Debt Assets 1,048,042 1,047, , ,792 Revenues increased by 15% YOY to $1.73 million in In Q1-2016, revenues dropped by 36% YOY to $0.37 million primarily because the company had an unusually high single payment in the previous year (Q1-2015). The company s share price is currently $0.04 per share, reflecting a market capitalization of $4.59 million, and an enterprise value of $5.2 million. The current EV to revenue ratio is at 3.02x versus the Health Care Technology industry average of 4.2x. We currently do not have a fair value estimate or rating on the company s shares.

6 Page 6 Disclaimers and Disclosure The opinions expressed in this report are the true opinions of the analyst(s) about any companies and industries mentioned. Any forward looking statements are our best estimates and opinions based upon information that is publicly available and that we believe to be correct, but we have not independently verified with respect to truth or correctness. There is no guarantee that our forecasts will materialize. Actual results will likely vary. Companies mentioned in this report may be covered by FRC under an issuer paid model or be candidates for coverage. Distribution procedure: our reports are distributed first to our web-based subscribers on the date shown on this report then made available to delayed access users through various other channels for a limited time. The performance of FRC s research is ranked by Investars. Full rankings and are available at To subscribe for real-time access to research, visit for subscription options. This report contains "forward looking" statements. Forward-looking statements regarding the Company, industry, and/or stock s performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products/services in the marketplace; acceptance in the marketplace of the Company's new product lines/services; competitive factors; new product/service introductions by others; technological changes; dependence on suppliers; systematic market risks and other risks discussed in the Company's periodic report filings, including interim reports, annual reports, and annual information forms filed with the various securities regulators. By making these forward looking statements, Fundamental Research Corp. and the analyst/author of this report undertakes no obligation to update these statements for revisions or changes after the date of this report.. Fundamental Research Corp DOES NOT MAKE ANY WARRANTIES, EXPRESSED OR IMPLIED, AS TO RESULTS TO BE OBTAINED FROM USING THIS INFORMATION AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OR FITNESS FOR A PARTICULAR USE. ANYONE USING THIS REPORT ASSUMES FULL RESPONSIBILITY FOR WHATEVER RESULTS THEY OBTAIN FROM WHATEVER USE THE INFORMATION WAS PUT TO. ALWAYS TALK TO YOUR FINANCIAL ADVISOR BEFORE YOU INVEST. WHETHER A STOCK SHOULD BE INCLUDED IN A PORTFOLIO DEPENDS ON ONE S RISK TOLERANCE, OBJECTIVES, SITUATION, RETURN ON OTHER ASSETS, ETC. ONLY YOUR INVESTMENT ADVISOR WHO KNOWS YOUR UNIQUE CIRCUMSTANCES CAN MAKE A PROPER RECOMMENDATION AS TO THE MERIT OF ANY PARTICULAR SECURITY FOR INCLUSION IN YOUR PORTFOLIO. This REPORT is solely for informative purposes and is not a solicitation or an offer to buy or sell any security. It is not intended as being a complete description of the company, industry, securities or developments referred to in the material. Any forecasts contained in this report were independently prepared unless otherwise stated, and HAVE NOT BEEN endorsed by the Management of the company which is the subject of this report. Additional information is available upon request. THIS REPORT IS COPYRIGHT. YOU MAY NOT REDISTRIBUTE THIS REPORT WITHOUT OUR PERMISSION. Please give proper credit, including citing Fundamental Research Corp and/or the analyst, when quoting information from this report. The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.